Eurecon Verlag: Pharma Trend Awards Best Pharmaceutical Companies and the Most Innovative Products 2021
The winner for the award "The Golden Tablet®" has been determined - BioNTech. In addition to the company's research activity, a large product pipeline with many innovations is decisive for the award, as well as the quality of the products. The ranking "Best Pharmaceutical Companies Germany 2021" was also published: Roche Pharma, Lilly, Bristol-Myers Squibb, Novartis Pharma and Amgen occupy places one to five in the Pharma Trend Image & Innovation Award survey.
Thirteen other winners were able to enjoy the award "Most Innovative Product". These include in the Rx category (prescription drugs): the COVID-19 vaccine Comirnaty® from BioNTech and Tolak® for the treatment of actinic keratoses from Pierre Fabre. Exeltis is awarded for both the oral contraceptive Slinda® and DeflaGyn® for the treatment of cervical dysplasia / erosions. In the Orphan Drugs category, Gilead Sciences' hepatitis D drug Hepcludex®, Kyowa Kirin's Poteligeo® for the treatment of mycosis fungoides and Sézary syndrome, and Incyte's Pemazyre® for the treatment of cholangiocarcinoma win.
In the Specialty Care segment, the prostate cancer drug Erleada® from Janssen-Cilag receives an award. The food supplement ImmunoBON® for allergy therapy by Bencard is the winner in the OTC category. The app MyIUS from Jenapharm, which accompanies users of intrauterine systems, was chosen in the Digital Health Applications category. Roche Diagnostics won in the Diagnostics category with the SARS-CoV-2 Rapid Antigen Test on the one hand, and the Avenio NGS Oncology Assay on the other. In the category Leap Innovations - Treatment of COVID-19, Formycon lands in first place followed by Ethris and Pieris Pharmaceuticals in second and third place.
The publication of the ranking and the presentation of the subject-specific awards took place on 14 September 2021 as a hybrid event in the Ehrensaal of the Deutsches Museum.
Further information on the ranking and the awards at https://pharma-trend.com/en/pharma-award/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210930005795/en/
Contact information
Eurecon Verlag GmbH
Dr. Dieter Jung, +49 8151 909801
CEO
Dieter.jung@eurecon.de
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Blue Shift Report Highlights Systemic Vulnerabilities Caused by the Hidden Cost of AI14.1.2026 11:00:00 EET | Press release
Arthur D. Little’s Blue Shift institute has published its latest report, AI’s Hidden Dependencies. This in-depth report, involving more than 50 experts, explores AI’s resource dependencies and the consequent direct systemic vulnerabilities for businesses and lays out strategic actions in response. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114966898/en/ Arthur D. Little’s Blue Shift Institute has published its latest report, AI’s Hidden Dependencies With AI’s adoption and usage expected to remain on its growth trajectory, so is its strain on resources. The report notably identifies three main areas of dependency: Environmental impacts, including emissions due to AI’s heavy energy usage and the manufacture of related hardware Energy supply, including increased electricity demand and strain on the grid Compute infrastructure, including supply chain choke points and dependencies on dominant providers As AI is now becomin
Klarna Expands Digital Bank Offer with Peer-to-Peer Payments14.1.2026 10:00:00 EET | Press release
Klarna, the global digital bank and flexible payments provider, has launched instant peer-to-peer payments in 13 European countries, marking the next step in its evolution as a digital bank. The new feature enables Klarna customers to send money to friends and family, whether splitting bills or gifting cash, directly from the Klarna app: as simple as handing someone cash, with the protection of a regulated bank. This launch takes Klarna deeper into everyday banking, turning Klarna into a central hub for day-to-day spending and money management. It comes on the back of the Klarna Balance accounts and the rapid adoption of Klarna Card, with over 4 million sign-ups just four months after launch. Sebastian Siemiatkowski, co-founder and CEO of Klarna commented: “Customers are sick of the friction and fees of traditional banking, which is why millions signed up to Klarna Card within a few months of launch. With peer-to-peer payments we’re making it even easier to manage all of your payments
Northern Trust Secures Expanded Mandate with Swedish Pension Provider AMF Tjänstepension AB14.1.2026 10:00:00 EET | Press release
Northern Trust (Nasdaq: NTRS) today announced that it has retained and expanded its mandate with AMF Tjänstepension AB (AMF), a leading Swedish pension provider. Under the renewed agreement, Northern Trust, which has serviced AMF for more than 20 years, will continue to serve as custodian for AMF’s global pension assets and add investment operations for trade services across AMF’s total portfolio, for both pension and fund company assets. AMF is one of Sweden’s leading pension companies, managing occupational pensions for millions of individuals. With a strong focus on delivering secure and sustainable retirement outcomes, AMF combines cost efficiency with long-term investment strategies to benefit its members. Petra Sjögerås, head of Nordic Region, Northern Trust said: “As a long-standing partner to institutions in the Nordic region, Northern Trust brings extensive experience and a solutions-oriented mindset to proactively support our clients to achieve their goals now and in the futu
Notice Concerning Change of Representative Executive Officer14.1.2026 09:14:00 EET | Press release
H.U. Group Holdings, Inc. (the Company) today announced that it has resolved, at a meeting of the Board of Directors held on January 14, 2026, to change the Company’s Representative Executive Officer as described below. 1. Name and job titles of newly appointed Representative Executive Officer Name New title Current title Goki Ishikawa Representative Executive Officer, President and Group CEO Managing Executive Officer 2. Name and job titles of retiring Representative Executive Officer Name New title Current title Shigekazu Takeuchi Director and Executive Officer Director, Representative Executive Officer, Chairman, President and Group CEO 3. Reason for change In May 2025, toward realizing its Vision for 2035, the Company announced its Medium-Term Management Plan “H.U. 2030” (MMP) as well as its CEO succession plan including the timing for the selection of the next CEO. As the succession plan progressed, the Company has recognized that Mr. Goki Ishikawa is the best to lead the executio
TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics14.1.2026 08:00:00 EET | Press release
Galderma (SIX: GALD) will present data on its innovative and industry-leading neuromodulator portfolio at the TOXINS 2026 International Conference in Madrid, Spain from January 14-17, 2026. The company will share data from five abstracts on two neuromodulators from its portfolio, Relfydess – the first and only ready-to-use liquid neuromodulator designed with PEARL Technology – and Dysport. Additionally, Galderma will be hosting a Relfydess Masterclass in which expert speakers will delve into the science and clinical data behind Relfydess. “At TOXINS 2026, we will demonstrate our continued leadership in neuromodulation through updates on our leading portfolio, and an educational session on Relfydess, an innovative, science-backed neuromodulator that delivers advanced performance. As the only company with a portfolio of neuromodulators, we’re building on our heritage in the space by developing next-generation solutions that address the evolving expectations of both patients and practitio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom